A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia 

Following 12 weeks of supplementation, this randomized double blind placebo controlled trial had 98 subjects with high cholesterol. There was a significant decrease in total cholesterol, triglycerides, LDL-cholesterol and VLDL cholesterol levels in the amla supplementation group, compared to the placebo group.  

References:

Upadya, H., Prabhu, S., Prasad, A., Subramanian, D., Gupta, S., & Goel, A. (2019). A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia. BMC complementary and alternative medicine, 19(1), 27. https://doi.org/10.1186/s12906-019-2430-y